Family Management Has Trimmed Microsoft (MSFT) Position By $498,916; 4 Bullish Analysts Covering Entellus Medical, Inc. (ENTL)

December 12, 2017 - By Migdalia James

Family Management Corp decreased Microsoft Corp (MSFT) stake by 8.71% reported in 2017Q2 SEC filing. Family Management Corp sold 7,337 shares as Microsoft Corp (MSFT)’s stock rose 4.75%. The Family Management Corp holds 76,863 shares with $5.30 million value, down from 84,200 last quarter. Microsoft Corp now has $658.44 billion valuation. The stock increased 0.14% or $0.12 during the last trading session, reaching $85.35. About 13.25M shares traded. Microsoft Corporation (NASDAQ:MSFT) has risen 34.52% since December 12, 2016 and is uptrending. It has outperformed by 17.82% the S&P500.

Among 6 analysts covering Entellus Medical (NASDAQ:ENTL), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Entellus Medical had 9 analyst reports since August 9, 2015 according to SRatingsIntel. Canaccord Genuity maintained Entellus Medical, Inc. (NASDAQ:ENTL) rating on Monday, October 16. Canaccord Genuity has “Hold” rating and $17.0 target. BTIG Research initiated the stock with “Buy” rating in Tuesday, June 14 report. The stock of Entellus Medical, Inc. (NASDAQ:ENTL) earned “Buy” rating by Canaccord Genuity on Sunday, August 9. The company was downgraded on Friday, December 8 by William Blair. The company was maintained on Monday, August 21 by Piper Jaffray. On Tuesday, September 29 the stock rating was maintained by Piper Jaffray with “”. The company was initiated on Thursday, October 6 by Deutsche Bank. See Entellus Medical, Inc. (NASDAQ:ENTL) latest ratings:

08/12/2017 Broker: William Blair Rating: Hold Downgrade
16/10/2017 Broker: Canaccord Genuity Rating: Hold New Target: $17.0 Maintain
12/09/2017 Broker: Canaccord Genuity Rating: Hold New Target: $17.0
21/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $21.0 Maintain

Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic and recurrent sinusitis. The company has market cap of $623.21 million. The firm offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation. It currently has negative earnings. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its battery power; Light Fiber, a single-use tool that provides real-time trans-illumination of the sinus cavity; Light Seeker, a tool with optical fibers embedded into the device to allow ear, nose, and throat physicians to access the frontal sinus and trans-illuminate the sinus cavity; Maxillary Seeker, a tool that allow users to find the correct angle to access the natural maxillary ostia; and Sphenoid Seeker/Freer, a two-in-one tool that enables ENT physicians to navigate access to the sphenoid ostium.

The stock increased 1.58% or $0.38 during the last trading session, reaching $24.46. About 275,945 shares traded. Entellus Medical, Inc. (NASDAQ:ENTL) has declined 17.59% since December 12, 2016 and is downtrending. It has underperformed by 34.29% the S&P500.

Among 35 analysts covering Microsoft Corporation (NASDAQ:MSFT), 29 have Buy rating, 2 Sell and 4 Hold. Therefore 83% are positive. Microsoft Corporation had 137 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Piper Jaffray on Tuesday, November 10. On Friday, October 27 the stock rating was maintained by Citigroup with “Sell”. The firm has “Buy” rating by UBS given on Friday, October 23. As per Thursday, September 3, the company rating was maintained by FBR Capital. On Tuesday, November 7 the stock rating was maintained by Tigress Financial with “Buy”. RBC Capital Markets maintained it with “Outperform” rating and $71 target in Friday, January 27 report. The stock has “Buy” rating by Stifel Nicolaus on Monday, August 21. The stock of Microsoft Corporation (NASDAQ:MSFT) earned “Buy” rating by Bernstein on Wednesday, September 27. The rating was maintained by KeyBanc Capital Markets on Sunday, July 16 with “Buy”. The firm has “Outperform” rating given on Wednesday, January 6 by RBC Capital Markets.

Analysts await Microsoft Corporation (NASDAQ:MSFT) to report earnings on January, 25. They expect $0.86 EPS, up 3.61% or $0.03 from last year’s $0.83 per share. MSFT’s profit will be $6.63 billion for 24.81 P/E if the $0.86 EPS becomes a reality. After $0.84 actual EPS reported by Microsoft Corporation for the previous quarter, Wall Street now forecasts 2.38% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By :